Suven Life Sciences Ltd (SUVEN)
₹258.85
Mkt cap
₹7,314 Cr
P/E ratio
—
P/B
11.56
Div yield
0.00%
ROE
−81.50%
ROCE
−79.50%
EPS (TTM)
—
Book value
₹22
52W range
124–403
Sector
Healthcare
Price history
Previous close
Suven Life Sciences is a clinical-stage biopharmaceutical company developing proprietary New Chemical Entities for central nervous system disorders. Its five clinical assets target agitation in Alzheimer’s dementia, narcolepsy, major depressive disorder and cognitive disorders. [1] [2]
NSE SUVENBSE 530239
Health check
Cautious
ProfitabilityWeak
GrowthLow
TechnicalsNeutral
52-week range
−35.82% from high₹259
₹124+108.56% from low₹403
Current
₹258.85
Prev close
₹264.20
Day
−2.02%
Price performance
1D
−1.78%
1W
−0.71%
1M
−20.09%
3M
−13.28%
6M
+19.40%
1Y
+33.81%
YTD
+57.06%
Financials
Revenue, profit & margin
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4 | 3 | 2 | 2 | 1 | 3 | 2 | 1 | 2 | 1 | 3 | 2 | 4 | |
| Expenses | 32 | 27 | 49 | 33 | 32 | 55 | 41 | 45 | 53 | 81 | 106 | 52 | 136 | |
| Operating Profit | -28 | -24 | -46 | -30 | -31 | -52 | -39 | -44 | -51 | -80 | -103 | -51 | -132 | |
| OPM % | -737% | -768% | -1,885% | -1,267% | -3,024% | -2,032% | -2,435% | -2,981% | -2,714% | -8,671% | -3,678% | -3,331% | -3,711% | |
| Other Income | 6 | 13 | 6 | 4 | 4 | 4 | 2 | 1 | 1 | 4 | 3 | 7 | 8 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | |
| Profit before tax | -24 | -13 | -42 | -28 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 | -128 | |
| Tax % | 0% | 0% | 0% | -4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
| Net Profit | -24 | -13 | -42 | -27 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 | -128 | |
| EPS in Rs | -1.10 | -0.58 | -1.91 | -1.22 | -1.29 | -2.28 | -1.79 | -2.01 | -2.36 | -3.40 | -4.48 | -1.73 | -4.83 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
5 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −2.68% · closed higher next day 0 of last 1
| Q1FY27† | |
|---|---|
| Broadcast | 6 Aug '26 |
| Earnings day | −2.68% |
| +1 day | −2.50% |
| +5 days | −0.03% |
| +15 days | +12.72% |
| +30 days | +4.59% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202665.47%Promoter
Promoters65.47%4.61
FIIs0.45%0.11
DIIs2.17%0.76
Public31.89%5.47
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Syngene Intl. | ₹402.70 | 61.15 | 16,256 | 0.31% | 32 | −45.17% | 833 | −8.55% | 9.99% |
| Indegene | ₹586.80 | 33.16 | 14,141 | 0.38% | 112 | +9.99% | 1,122 | +39.55% | 18.82% |
| Suven Life Scie. | ₹258.85 | — | 7,314 | 0.00% | −128 | −147.69% | 4 | +90.91% | −79.54% |
| Vimta Labs | ₹484.90 | 26.60 | 2,168 | 0.41% | 21 | +3.46% | 112 | +9.95% | 25.23% |
| Fabtech Tech. | ₹123.90 | 18.50 | 551 | 0.48% | 15 | −67.06% | 92 | −24.19% | 13.88% |
| Novelix Pharma. | ₹68.57 | 53.93 | 195 | 0.00% | 1 | +972.73% | 37 | +65.15% | 10.87% |
| Bilcare | ₹75.33 | 8.91 | 177 | 0.00% | 15 | +473.06% | 226 | +21.20% | 7.06% |
| Median: 9 Co. | ₹123.90 | 29.95 | 551 | 0.00% | 15 | +9.99% | 92 | +30.38% | 10.87% |
Filings
Annual reports15
Concall transcripts35
PPTJul 2021TranscriptFeb 2020TranscriptNov 2019PPTNov 2019TranscriptAug 2019PPTAug 2019TranscriptMay 2019PPTMay 2019PPTMay 2019TranscriptFeb 2019PPTFeb 2019PPTFeb 2019PPTFeb 2019TranscriptNov 2018PPTNov 2018PPTNov 2018TranscriptAug 2018PPTAug 2018TranscriptMay 2018PPTMay 2018PPTJan 2018PPTDec 2017TranscriptNov 2017PPTNov 2017
Credit ratings6
Announcements5
Board Meeting Intimation for Consideration Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended 30Th September, 2026 29 Oct - Board meets on 5 November 2026 to approve Q2 and half-year FY2026-27 results.Announcement under Regulation 30 (LODR)-Newspaper Publication 23 Oct - Special Window for Re-lodgment of transfer requests of Physical sharesCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 OctClosure of Trading Window 28 Sep - Trading window closed1 October 2026 until 48 hours after Q2 FY27 results.Announcement under Regulation 30 (LODR)-Press Release / Media Release 3 Sep - Suven completed Phase-3 Masupirdine enrollment; 424 patients randomized, topline results expected by May 2027.